Daniel Barocas
Faculty Member
Last active: 3/27/2014


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF (2014) Cancer 120(8): 1263-71
    › Primary publication · 24510400 (PubMed) · PMC4930672 (PubMed Central)
  2. Variation in the intensity of hematuria evaluation: a target for primary care quality improvement. Friedlander DF, Resnick MJ, You C, Bassett J, Yarlagadda V, Penson DF, Barocas DA (2014) Am J Med 127(7): 633-640.e11
    › Primary publication · 24486290 (PubMed) · PMC4074456 (PubMed Central)
  3. Racial variation in the quality of surgical care for bladder cancer. Barocas DA, Alvarez J, Koyama T, Anderson CB, Gray DT, Fowke JH, You C, Chang SS, Cookson MS, Smith JA, Penson DF (2014) Cancer 120(7): 1018-25
    › Primary publication · 24339051 (PubMed) · PMC3961490 (PubMed Central)
  4. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup A, Wu XC, Penson DF (2013) J Comp Eff Res 2(4): 445-60
    › Primary publication · 24236685 (PubMed) · PMC4920086 (PubMed Central)
  5. Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer. Barocas DA, Liu A, Burks FN, Suh RS, Schuster TG, Bradford T, Moylan DA, Knapp PM, Murtagh DS, Morris D, Dunn RL, Montie JE, Miller DC (2013) J Urol 190(6): 2011-6
    › Primary publication · 23792129 (PubMed)
  6. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Barocas DA, Grubb R, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED (2013) Cancer 119(12): 2223-9
    › Primary publication · 23559420 (PubMed)
  7. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Ramsay C, Pickard R, Robertson C, Close A, Vale L, Armstrong N, Barocas DA, Eden CG, Fraser C, Gurung T, Jenkinson D, Jia X, Lam TB, Mowatt G, Neal DE, Robinson MC, Royle J, Rushton SP, Sharma P, Shirley MD, Soomro N (2012) Health Technol Assess 16(41): 1-313
    › Primary publication · 23127367 (PubMed) · PMC4780976 (PubMed Central)
  8. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, Messing EM, Miller SD, Peterson AC, Turk TM, Weitzel W, American Urological Association (2012) J Urol 188(6 Suppl): 2473-81
    › Primary publication · 23098784 (PubMed)
  9. Centralization of radical prostatectomy in the United States. Anderson CB, Penson DF, Ni S, Makarov DV, Barocas DA (2013) J Urol 189(2): 500-6
    › Primary publication · 23069384 (PubMed)
  10. Racial variation in the quality of surgical care for prostate cancer. Barocas DA, Gray DT, Fowke JH, Mercaldo ND, Blume JD, Chang SS, Cookson MS, Smith JA, Penson DF (2012) J Urol 188(4): 1279-85
    › Primary publication · 22902011 (PubMed) · PMC3770766 (PubMed Central)
  11. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. Patel SG, Penson DF, Pabla B, Clark PE, Cookson MS, Chang SS, Herrell SD, Smith JA, Barocas DA (2012) J Urol 187(3): 816-21
    › Primary publication · 22248514 (PubMed)
  12. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Anderson CB, Pyle AL, Woodworth A, Cookson MS, Smith JA, Barocas DA (2012) Prostate Cancer Prostatic Dis 15(2): 182-8
    › Primary publication · 22105412 (PubMed)
  13. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Penson DF, Smith JA, Barocas DA (2011) J Urol 186(6): 2221-7
    › Primary publication · 22014803 (PubMed)
  14. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. Morgan TM, Keegan KA, Barocas DA, Ruhotina N, Phillips SE, Chang SS, Penson DF, Clark PE, Smith JA, Cookson MS (2011) J Urol 186(3): 829-34
    › Primary publication · 21788035 (PubMed) · PMC6472701 (PubMed Central)
  15. Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. Barocas DA, Motley S, Cookson MS, Chang SS, Penson DF, Dai Q, Milne G, Roberts LJ, Morrow J, Concepcion RS, Smith JA, Fowke JH (2011) J Urol 185(6): 2102-7
    › Primary publication · 21496850 (PubMed) · PMC3093434 (PubMed Central)
  16. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. Thompson IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA (2011) World J Urol 29(1): 15-20
    › Primary publication · 21079968 (PubMed)
  17. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ, Aghazadeh M, Smith JA, Barocas DA (2011) J Urol 185(1): 90-6
    › Primary publication · 21074802 (PubMed) · PMC3049248 (PubMed Central)
  18. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Wills ML, Shappell SB, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA (2010) J Urol 184(4): 1334-40
    › Primary publication · 20723932 (PubMed)
  19. Smaller prostate size predicts high grade prostate cancer at final pathology. Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, Fowke JH, Herrell SD, Baumgartner R, Chan R, Mishra V, Blume JD, Smith JA, Barocas DA (2010) J Urol 184(3): 930-7
    › Primary publication · 20643423 (PubMed)
  20. Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. Barocas DA, Penson DF (2010) BJU Int 106(3): 322-8
    › Primary publication · 20553251 (PubMed) · PMC2910169 (PubMed Central)
  21. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. Barocas DA, Salem S, Kordan Y, Herrell SD, Chang SS, Clark PE, Davis R, Baumgartner R, Phillips S, Cookson MS, Smith JA (2010) J Urol 183(3): 990-6
    › Primary publication · 20083261 (PubMed)